

A practical guide for providers on helping patients find Evekeo during the shortage. Includes 5 actionable steps, alternative options, and workflow tips.
As a prescriber, you already know the stimulant shortage is impacting your patients. But for those on Evekeo (amphetamine sulfate), the challenge is even greater. Evekeo's niche 1:1 racemic amphetamine formulation, limited manufacturer base, and small market share make it one of the hardest stimulants to source in 2026.
Your patients are frustrated, and many are spending hours calling pharmacies only to hear "we don't have it" over and over. This guide gives you practical steps to help — from verifying stock before prescribing to developing contingency plans.
As of early 2026, Evekeo availability remains inconsistent across the country. Key factors driving the shortage include:
The result: even when Evekeo is technically in production, getting it to the right pharmacy at the right time remains a challenge.
Understanding the patient experience helps frame your approach:
The single most impactful thing you can do is confirm that a pharmacy has Evekeo in stock before e-prescribing. This prevents the demoralizing cycle of patients going to a pharmacy only to be turned away.
Use Medfinder for Providers to check real-time availability at pharmacies near your patient. Staff can do this in seconds during the appointment or as part of prescription processing.
Identify 3-5 pharmacies in your area that have been able to source Evekeo reliably. This typically includes:
Maintain a list in your EHR or office reference and update it monthly. Share this list with patients proactively.
When clinically appropriate, prescribing flexibility can increase the odds of a successful fill:
For every patient on Evekeo, document a contingency plan in the chart:
Having this documented means a covering provider can act quickly if you're unavailable when a patient can't fill their prescription.
Even when Evekeo is found, cost can prevent patients from filling. At each visit, briefly address:
Direct patients to our guide on how to save money on Evekeo, or review our provider's guide to helping patients save on Evekeo.
When Evekeo is genuinely unavailable and treatment continuity is at risk, the following alternatives may be appropriate:
For patient-facing information on alternatives, share our guide on alternatives to Evekeo.
Implementing a few workflow changes can reduce the burden on both staff and patients:
Train front desk or nursing staff to check Evekeo availability on Medfinder before the patient's appointment. This way, you can discuss pharmacy options and send the prescription to a confirmed location during the visit.
Flag Evekeo patients in your scheduling system. When their refill is approaching (5-7 days before), have staff proactively check stock and notify the patient of where to go.
Create a standard message (via patient portal or letter) that includes:
Keep a template for Evekeo prior authorizations that includes standard clinical justification language. Having this ready reduces turnaround time when insurance denials occur.
The Evekeo shortage places an extra burden on providers who are already managing complex patient panels. But a proactive approach — using Medfinder for Providers, building a reliable pharmacy network, documenting backup plans, and addressing cost barriers — can significantly reduce treatment disruptions for your patients.
For the broader shortage picture, see our clinical briefing on the Evekeo shortage. For drug interaction considerations when switching medications, review our article on Evekeo drug interactions.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.